A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
Background Galcanezumab, a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide, has demonstrated in previous Phase 2 and Phase 3 clinical studies (≤6-month of treatment) a reduction in the number of migraine headache days and improved patients’ functioning. Th...
Gespeichert in:
| Veröffentlicht in: | BMC neurology Jg. 18; H. 1; S. 188 - 12 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
London
BioMed Central
09.11.2018
BioMed Central Ltd Springer Nature B.V BMC |
| Schlagworte: | |
| ISSN: | 1471-2377, 1471-2377 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Background
Galcanezumab, a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide, has demonstrated in previous Phase 2 and Phase 3 clinical studies (≤6-month of treatment) a reduction in the number of migraine headache days and improved patients’ functioning. This study evaluated the safety and tolerability, as well as the effectiveness of galcanezumab for up to 12 months of treatment in patients with migraine.
Methods
Patients diagnosed with episodic or chronic migraine, 18 to 65 years old, that were not exposed previously to galcanezumab, were randomized to receive galcanezumab 120 mg or 240 mg, administered subcutaneously once monthly for a year. Safety and tolerability were evaluated by frequency of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events (AEs) leading to study discontinuation. Laboratory values, vital signs, electrocardiograms, and suicidality were also analyzed. Additionally, overall change from baseline in the number of monthly migraine headache days, functioning, and disability were assessed.
Results
One hundred thirty five patients were randomized to each galcanezumab dose group. The majority of patients were female (> 80%) and on average were 42 years old with 10.6 migraine headache days per month at baseline. 77.8% of the patients completed the open-label treatment phase, 3.7% of patients experienced an SAE, and 4.8% discontinued due to AEs. TEAEs with a frequency ≥ 10% of patients in either dose group were injection site pain, nasopharyngitis, upper respiratory tract infection, injection site reaction, back pain, and sinusitis. Laboratory values, vital signs, or electrocardiograms did not show anyclinically meaningful differences between galcanezumab dosesOverall mean reduction in monthly migraine headache days over 12 months for the galcanezumab dose groups were 5.6 (120 mg) and 6.5 (240 mg). Level of functioning was improved and headache-related disability was reduced in both dose groups.
Conclusion
Twelve months of treatment with self-administered injections of galcanezumab was safe and associated with a reduction in the number of monthly migraine headache days. Safety and tolerability of the 2 galcanezumab dosing regimens were comparable.
Trial registration
ClinicalTrials.gov as
NCT02614287
, posted November 15, 2015. These data were previously presented as a poster at the International Headache Congress 2017: PO-01-184, Late-Breaking Abstracts of the 2017 International Headache Congress. (2017). Cephalalgia, 37(1_suppl), 319–374. |
|---|---|
| AbstractList | Galcanezumab, a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide, has demonstrated in previous Phase 2 and Phase 3 clinical studies (≤6-month of treatment) a reduction in the number of migraine headache days and improved patients' functioning. This study evaluated the safety and tolerability, as well as the effectiveness of galcanezumab for up to 12 months of treatment in patients with migraine.BACKGROUNDGalcanezumab, a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide, has demonstrated in previous Phase 2 and Phase 3 clinical studies (≤6-month of treatment) a reduction in the number of migraine headache days and improved patients' functioning. This study evaluated the safety and tolerability, as well as the effectiveness of galcanezumab for up to 12 months of treatment in patients with migraine.Patients diagnosed with episodic or chronic migraine, 18 to 65 years old, that were not exposed previously to galcanezumab, were randomized to receive galcanezumab 120 mg or 240 mg, administered subcutaneously once monthly for a year. Safety and tolerability were evaluated by frequency of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events (AEs) leading to study discontinuation. Laboratory values, vital signs, electrocardiograms, and suicidality were also analyzed. Additionally, overall change from baseline in the number of monthly migraine headache days, functioning, and disability were assessed.METHODSPatients diagnosed with episodic or chronic migraine, 18 to 65 years old, that were not exposed previously to galcanezumab, were randomized to receive galcanezumab 120 mg or 240 mg, administered subcutaneously once monthly for a year. Safety and tolerability were evaluated by frequency of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events (AEs) leading to study discontinuation. Laboratory values, vital signs, electrocardiograms, and suicidality were also analyzed. Additionally, overall change from baseline in the number of monthly migraine headache days, functioning, and disability were assessed.One hundred thirty five patients were randomized to each galcanezumab dose group. The majority of patients were female (> 80%) and on average were 42 years old with 10.6 migraine headache days per month at baseline. 77.8% of the patients completed the open-label treatment phase, 3.7% of patients experienced an SAE, and 4.8% discontinued due to AEs. TEAEs with a frequency ≥ 10% of patients in either dose group were injection site pain, nasopharyngitis, upper respiratory tract infection, injection site reaction, back pain, and sinusitis. Laboratory values, vital signs, or electrocardiograms did not show anyclinically meaningful differences between galcanezumab dosesOverall mean reduction in monthly migraine headache days over 12 months for the galcanezumab dose groups were 5.6 (120 mg) and 6.5 (240 mg). Level of functioning was improved and headache-related disability was reduced in both dose groups.RESULTSOne hundred thirty five patients were randomized to each galcanezumab dose group. The majority of patients were female (> 80%) and on average were 42 years old with 10.6 migraine headache days per month at baseline. 77.8% of the patients completed the open-label treatment phase, 3.7% of patients experienced an SAE, and 4.8% discontinued due to AEs. TEAEs with a frequency ≥ 10% of patients in either dose group were injection site pain, nasopharyngitis, upper respiratory tract infection, injection site reaction, back pain, and sinusitis. Laboratory values, vital signs, or electrocardiograms did not show anyclinically meaningful differences between galcanezumab dosesOverall mean reduction in monthly migraine headache days over 12 months for the galcanezumab dose groups were 5.6 (120 mg) and 6.5 (240 mg). Level of functioning was improved and headache-related disability was reduced in both dose groups.Twelve months of treatment with self-administered injections of galcanezumab was safe and associated with a reduction in the number of monthly migraine headache days. Safety and tolerability of the 2 galcanezumab dosing regimens were comparable.CONCLUSIONTwelve months of treatment with self-administered injections of galcanezumab was safe and associated with a reduction in the number of monthly migraine headache days. Safety and tolerability of the 2 galcanezumab dosing regimens were comparable.ClinicalTrials.gov as NCT02614287 , posted November 15, 2015. These data were previously presented as a poster at the International Headache Congress 2017: PO-01-184, Late-Breaking Abstracts of the 2017 International Headache Congress. (2017). Cephalalgia, 37(1_suppl), 319-374.TRIAL REGISTRATIONClinicalTrials.gov as NCT02614287 , posted November 15, 2015. These data were previously presented as a poster at the International Headache Congress 2017: PO-01-184, Late-Breaking Abstracts of the 2017 International Headache Congress. (2017). Cephalalgia, 37(1_suppl), 319-374. Abstract Background Galcanezumab, a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide, has demonstrated in previous Phase 2 and Phase 3 clinical studies (≤6-month of treatment) a reduction in the number of migraine headache days and improved patients’ functioning. This study evaluated the safety and tolerability, as well as the effectiveness of galcanezumab for up to 12 months of treatment in patients with migraine. Methods Patients diagnosed with episodic or chronic migraine, 18 to 65 years old, that were not exposed previously to galcanezumab, were randomized to receive galcanezumab 120 mg or 240 mg, administered subcutaneously once monthly for a year. Safety and tolerability were evaluated by frequency of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events (AEs) leading to study discontinuation. Laboratory values, vital signs, electrocardiograms, and suicidality were also analyzed. Additionally, overall change from baseline in the number of monthly migraine headache days, functioning, and disability were assessed. Results One hundred thirty five patients were randomized to each galcanezumab dose group. The majority of patients were female (> 80%) and on average were 42 years old with 10.6 migraine headache days per month at baseline. 77.8% of the patients completed the open-label treatment phase, 3.7% of patients experienced an SAE, and 4.8% discontinued due to AEs. TEAEs with a frequency ≥ 10% of patients in either dose group were injection site pain, nasopharyngitis, upper respiratory tract infection, injection site reaction, back pain, and sinusitis. Laboratory values, vital signs, or electrocardiograms did not show anyclinically meaningful differences between galcanezumab dosesOverall mean reduction in monthly migraine headache days over 12 months for the galcanezumab dose groups were 5.6 (120 mg) and 6.5 (240 mg). Level of functioning was improved and headache-related disability was reduced in both dose groups. Conclusion Twelve months of treatment with self-administered injections of galcanezumab was safe and associated with a reduction in the number of monthly migraine headache days. Safety and tolerability of the 2 galcanezumab dosing regimens were comparable. Trial registration ClinicalTrials.gov as NCT02614287, posted November 15, 2015. These data were previously presented as a poster at the International Headache Congress 2017: PO-01-184, Late-Breaking Abstracts of the 2017 International Headache Congress. (2017). Cephalalgia, 37(1_suppl), 319–374. Galcanezumab, a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide, has demonstrated in previous Phase 2 and Phase 3 clinical studies (≤6-month of treatment) a reduction in the number of migraine headache days and improved patients' functioning. This study evaluated the safety and tolerability, as well as the effectiveness of galcanezumab for up to 12 months of treatment in patients with migraine. Patients diagnosed with episodic or chronic migraine, 18 to 65 years old, that were not exposed previously to galcanezumab, were randomized to receive galcanezumab 120 mg or 240 mg, administered subcutaneously once monthly for a year. Safety and tolerability were evaluated by frequency of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events (AEs) leading to study discontinuation. Laboratory values, vital signs, electrocardiograms, and suicidality were also analyzed. Additionally, overall change from baseline in the number of monthly migraine headache days, functioning, and disability were assessed. One hundred thirty five patients were randomized to each galcanezumab dose group. The majority of patients were female (> 80%) and on average were 42 years old with 10.6 migraine headache days per month at baseline. 77.8% of the patients completed the open-label treatment phase, 3.7% of patients experienced an SAE, and 4.8% discontinued due to AEs. TEAEs with a frequency ≥ 10% of patients in either dose group were injection site pain, nasopharyngitis, upper respiratory tract infection, injection site reaction, back pain, and sinusitis. Laboratory values, vital signs, or electrocardiograms did not show anyclinically meaningful differences between galcanezumab dosesOverall mean reduction in monthly migraine headache days over 12 months for the galcanezumab dose groups were 5.6 (120 mg) and 6.5 (240 mg). Level of functioning was improved and headache-related disability was reduced in both dose groups. Twelve months of treatment with self-administered injections of galcanezumab was safe and associated with a reduction in the number of monthly migraine headache days. Safety and tolerability of the 2 galcanezumab dosing regimens were comparable. ClinicalTrials.gov as NCT02614287 , posted November 15, 2015. These data were previously presented as a poster at the International Headache Congress 2017: PO-01-184, Late-Breaking Abstracts of the 2017 International Headache Congress. (2017). Cephalalgia, 37(1_suppl), 319-374. Background Galcanezumab, a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide, has demonstrated in previous Phase 2 and Phase 3 clinical studies (≤6-month of treatment) a reduction in the number of migraine headache days and improved patients’ functioning. This study evaluated the safety and tolerability, as well as the effectiveness of galcanezumab for up to 12 months of treatment in patients with migraine. Methods Patients diagnosed with episodic or chronic migraine, 18 to 65 years old, that were not exposed previously to galcanezumab, were randomized to receive galcanezumab 120 mg or 240 mg, administered subcutaneously once monthly for a year. Safety and tolerability were evaluated by frequency of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events (AEs) leading to study discontinuation. Laboratory values, vital signs, electrocardiograms, and suicidality were also analyzed. Additionally, overall change from baseline in the number of monthly migraine headache days, functioning, and disability were assessed. Results One hundred thirty five patients were randomized to each galcanezumab dose group. The majority of patients were female (> 80%) and on average were 42 years old with 10.6 migraine headache days per month at baseline. 77.8% of the patients completed the open-label treatment phase, 3.7% of patients experienced an SAE, and 4.8% discontinued due to AEs. TEAEs with a frequency ≥ 10% of patients in either dose group were injection site pain, nasopharyngitis, upper respiratory tract infection, injection site reaction, back pain, and sinusitis. Laboratory values, vital signs, or electrocardiograms did not show anyclinically meaningful differences between galcanezumab dosesOverall mean reduction in monthly migraine headache days over 12 months for the galcanezumab dose groups were 5.6 (120 mg) and 6.5 (240 mg). Level of functioning was improved and headache-related disability was reduced in both dose groups. Conclusion Twelve months of treatment with self-administered injections of galcanezumab was safe and associated with a reduction in the number of monthly migraine headache days. Safety and tolerability of the 2 galcanezumab dosing regimens were comparable. Trial registration ClinicalTrials.gov as NCT02614287, posted November 15, 2015. These data were previously presented as a poster at the International Headache Congress 2017: PO-01-184, Late-Breaking Abstracts of the 2017 International Headache Congress. (2017). Cephalalgia, 37(1_suppl), 319–374. Background Galcanezumab, a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide, has demonstrated in previous Phase 2 and Phase 3 clinical studies ([less than or equai to]6-month of treatment) a reduction in the number of migraine headache days and improved patients' functioning. This study evaluated the safety and tolerability, as well as the effectiveness of galcanezumab for up to 12 months of treatment in patients with migraine. Methods Patients diagnosed with episodic or chronic migraine, 18 to 65 years old, that were not exposed previously to galcanezumab, were randomized to receive galcanezumab 120 mg or 240 mg, administered subcutaneously once monthly for a year. Safety and tolerability were evaluated by frequency of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events (AEs) leading to study discontinuation. Laboratory values, vital signs, electrocardiograms, and suicidality were also analyzed. Additionally, overall change from baseline in the number of monthly migraine headache days, functioning, and disability were assessed. Results One hundred thirty five patients were randomized to each galcanezumab dose group. The majority of patients were female (> 80%) and on average were 42 years old with 10.6 migraine headache days per month at baseline. 77.8% of the patients completed the open-label treatment phase, 3.7% of patients experienced an SAE, and 4.8% discontinued due to AEs. TEAEs with a frequency [greater than or equai to] 10% of patients in either dose group were injection site pain, nasopharyngitis, upper respiratory tract infection, injection site reaction, back pain, and sinusitis. Laboratory values, vital signs, or electrocardiograms did not show anyclinically meaningful differences between galcanezumab dosesOverall mean reduction in monthly migraine headache days over 12 months for the galcanezumab dose groups were 5.6 (120 mg) and 6.5 (240 mg). Level of functioning was improved and headache-related disability was reduced in both dose groups. Conclusion Twelve months of treatment with self-administered injections of galcanezumab was safe and associated with a reduction in the number of monthly migraine headache days. Safety and tolerability of the 2 galcanezumab dosing regimens were comparable. Trial registration ClinicalTrials.gov as NCT02614287, posted November 15, 2015. These data were previously presented as a poster at the International Headache Congress 2017: PO-01-184, Late-Breaking s of the 2017 International Headache Congress. (2017). Cephalalgia, 37(1_suppl), 319-374. Keywords: Migraine, Headache, Galcanezumab, CGRP Background Galcanezumab, a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide, has demonstrated in previous Phase 2 and Phase 3 clinical studies (≤6-month of treatment) a reduction in the number of migraine headache days and improved patients’ functioning. This study evaluated the safety and tolerability, as well as the effectiveness of galcanezumab for up to 12 months of treatment in patients with migraine. Methods Patients diagnosed with episodic or chronic migraine, 18 to 65 years old, that were not exposed previously to galcanezumab, were randomized to receive galcanezumab 120 mg or 240 mg, administered subcutaneously once monthly for a year. Safety and tolerability were evaluated by frequency of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events (AEs) leading to study discontinuation. Laboratory values, vital signs, electrocardiograms, and suicidality were also analyzed. Additionally, overall change from baseline in the number of monthly migraine headache days, functioning, and disability were assessed. Results One hundred thirty five patients were randomized to each galcanezumab dose group. The majority of patients were female (> 80%) and on average were 42 years old with 10.6 migraine headache days per month at baseline. 77.8% of the patients completed the open-label treatment phase, 3.7% of patients experienced an SAE, and 4.8% discontinued due to AEs. TEAEs with a frequency ≥ 10% of patients in either dose group were injection site pain, nasopharyngitis, upper respiratory tract infection, injection site reaction, back pain, and sinusitis. Laboratory values, vital signs, or electrocardiograms did not show anyclinically meaningful differences between galcanezumab dosesOverall mean reduction in monthly migraine headache days over 12 months for the galcanezumab dose groups were 5.6 (120 mg) and 6.5 (240 mg). Level of functioning was improved and headache-related disability was reduced in both dose groups. Conclusion Twelve months of treatment with self-administered injections of galcanezumab was safe and associated with a reduction in the number of monthly migraine headache days. Safety and tolerability of the 2 galcanezumab dosing regimens were comparable. Trial registration ClinicalTrials.gov as NCT02614287 , posted November 15, 2015. These data were previously presented as a poster at the International Headache Congress 2017: PO-01-184, Late-Breaking Abstracts of the 2017 International Headache Congress. (2017). Cephalalgia, 37(1_suppl), 319–374. Galcanezumab, a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide, has demonstrated in previous Phase 2 and Phase 3 clinical studies ([less than or equai to]6-month of treatment) a reduction in the number of migraine headache days and improved patients' functioning. This study evaluated the safety and tolerability, as well as the effectiveness of galcanezumab for up to 12 months of treatment in patients with migraine. One hundred thirty five patients were randomized to each galcanezumab dose group. The majority of patients were female (> 80%) and on average were 42 years old with 10.6 migraine headache days per month at baseline. 77.8% of the patients completed the open-label treatment phase, 3.7% of patients experienced an SAE, and 4.8% discontinued due to AEs. TEAEs with a frequency [greater than or equai to] 10% of patients in either dose group were injection site pain, nasopharyngitis, upper respiratory tract infection, injection site reaction, back pain, and sinusitis. Laboratory values, vital signs, or electrocardiograms did not show anyclinically meaningful differences between galcanezumab dosesOverall mean reduction in monthly migraine headache days over 12 months for the galcanezumab dose groups were 5.6 (120 mg) and 6.5 (240 mg). Level of functioning was improved and headache-related disability was reduced in both dose groups. Twelve months of treatment with self-administered injections of galcanezumab was safe and associated with a reduction in the number of monthly migraine headache days. Safety and tolerability of the 2 galcanezumab dosing regimens were comparable. |
| ArticleNumber | 188 |
| Audience | Academic |
| Author | Wang, Shufang Van Dycke, Annelies Stauffer, Virginia L. Sides, Ryan Selzler, Katherine J. Camporeale, Angelo Kudrow, David |
| Author_xml | – sequence: 1 givenname: Angelo surname: Camporeale fullname: Camporeale, Angelo organization: Eli Lilly Italia – sequence: 2 givenname: David surname: Kudrow fullname: Kudrow, David organization: California Medical Clinic for Headache, UCLA David Geffen School of Medicine – sequence: 3 givenname: Ryan surname: Sides fullname: Sides, Ryan organization: Eli Lilly and Company Corporate Center – sequence: 4 givenname: Shufang surname: Wang fullname: Wang, Shufang organization: Eli Lilly and Company Corporate Center – sequence: 5 givenname: Annelies surname: Van Dycke fullname: Van Dycke, Annelies organization: Neurology Department, AZ Sint-Jan Brugge – sequence: 6 givenname: Katherine J. surname: Selzler fullname: Selzler, Katherine J. organization: Eli Lilly and Company Corporate Center – sequence: 7 givenname: Virginia L. surname: Stauffer fullname: Stauffer, Virginia L. email: vstauffer@lilly.com organization: Eli Lilly and Company Corporate Center |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30413151$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ks1u1DAUhS1URNuBB2CDLLFh0RRf2_nbII0qKJUqsQGxtGzHzrhK7MFOQMPT4zCl7VSAIiWR851zdU_OKTrywRuEXgI5B2iqtwlo07CCQFMAtKygT9AJ8BoKyur66MH7MTpN6YYQqBsOz9AxIxwYlHCCvq7xdiOTwewMD8H3xWTieIbD1vhikMoMOElrph1O09ztcLD4Ug5aevNzHqXCzuOtnJzxU8I_3LTBo-ujdN48R0-tHJJ5cftcoS8f3n---Fhcf7q8ulhfF7oibCo0B6IV55VSxgK3tOVl2XKtpGSMcU1ZxbuWVaA6ohvbSUs7Ii0wQ62SirIVutr7dkHeiG10o4w7EaQTvw9C7IWMk9ODEVzloGjdlWDyQMh2lVZQNZVqVdnlQFbo3d5rO6vRdDpvFeVwYHr4xbuN6MN3UVHG67bKBm9uDWL4Nps0idElbYYh5xXmJCgwSiln0GT09SP0JszR56gWquQ838k91cu8gPM25Ll6MRXrssojOSULdf4XKl-dGZ3OlbEunx8IXj1c9G7DP7XIAOwBHUNK0dg7BIhYqif21RM5UbFUTyx_on6k0W7K3QhLVm74r5LulSlP8b2J91n8W_QL1PrqOw |
| CitedBy_id | crossref_primary_10_1111_ene_15816 crossref_primary_10_1080_00207454_2022_2098732 crossref_primary_10_1080_03007995_2022_2059975 crossref_primary_10_1080_14712598_2020_1751114 crossref_primary_10_1186_s12883_020_1609_7 crossref_primary_10_1080_14740338_2020_1811229 crossref_primary_10_1111_joim_13506 crossref_primary_10_1186_s10194_022_01387_y crossref_primary_10_1007_s11136_020_02632_0 crossref_primary_10_2147_JPR_S222604 crossref_primary_10_1080_14740338_2021_1942839 crossref_primary_10_36290_neu_2019_141 crossref_primary_10_1007_s11916_023_01155_w crossref_primary_10_1136_dtb_2020_000037 crossref_primary_10_3390_cells12010143 crossref_primary_10_3389_fphys_2021_820006 crossref_primary_10_1111_head_13601 crossref_primary_10_1016_j_pharmthera_2020_107528 crossref_primary_10_1007_s10072_019_03769_8 crossref_primary_10_3390_ph14090924 crossref_primary_10_1016_j_bone_2020_115645 crossref_primary_10_4103_0028_3886_315989 crossref_primary_10_1097_WCO_0000000000000935 crossref_primary_10_1177_03331024221128250 crossref_primary_10_1007_s12325_022_02346_4 crossref_primary_10_1080_01616412_2021_1940672 crossref_primary_10_1007_s00415_020_09707_5 crossref_primary_10_1007_s15005_020_1258_9 crossref_primary_10_1136_jnnp_2021_327480 crossref_primary_10_1007_s40120_021_00236_5 crossref_primary_10_1111_head_14439 crossref_primary_10_1007_s40120_020_00214_3 crossref_primary_10_1186_s10194_020_01211_5 crossref_primary_10_3390_jcm11154359 crossref_primary_10_1111_head_14007 crossref_primary_10_1111_head_14642 crossref_primary_10_1177_0333102420920642 crossref_primary_10_1186_s10194_018_0955_y crossref_primary_10_1186_s10194_019_0999_7 crossref_primary_10_1016_j_ncl_2020_09_001 crossref_primary_10_1007_s12325_021_01911_7 crossref_primary_10_1080_14737175_2020_1772758 crossref_primary_10_1111_head_13591 crossref_primary_10_1177_25158163211033969 crossref_primary_10_1097_MED_0000000000000717 crossref_primary_10_1016_j_jdcr_2021_01_015 crossref_primary_10_1212_WNL_0000000000010600 crossref_primary_10_1016_S0140_6736_19_32504_8 crossref_primary_10_3390_ph14070700 crossref_primary_10_1186_s10194_021_01323_6 crossref_primary_10_1002_brb3_70447 crossref_primary_10_1080_14712598_2019_1671350 crossref_primary_10_2147_JPR_S287781 crossref_primary_10_1007_s40263_021_00834_9 crossref_primary_10_1186_s10194_024_01721_6 crossref_primary_10_1111_ene_14143 crossref_primary_10_1177_03331024251365206 crossref_primary_10_1080_14740338_2021_1866536 crossref_primary_10_1007_s40259_022_00530_0 crossref_primary_10_3390_pharmaceutics15010145 crossref_primary_10_1007_s12325_020_01319_9 crossref_primary_10_1007_s11916_022_01064_4 crossref_primary_10_1016_j_xkme_2025_101092 crossref_primary_10_1080_14712598_2020_1800635 crossref_primary_10_1111_head_13661 crossref_primary_10_1111_head_14234 crossref_primary_10_1111_head_14153 crossref_primary_10_1016_j_pediatrneurol_2024_05_013 crossref_primary_10_1111_head_14390 crossref_primary_10_1186_s10194_019_1000_5 crossref_primary_10_1186_s10194_020_01148_9 crossref_primary_10_36290_far_2022_020 crossref_primary_10_1186_s10194_020_1085_x crossref_primary_10_1186_s12883_020_01633_3 crossref_primary_10_1080_14712598_2019_1626370 crossref_primary_10_1177_03331024221076485 crossref_primary_10_1016_j_bpa_2020_08_002 crossref_primary_10_3390_ph14030245 crossref_primary_10_1002_cpdd_1599 crossref_primary_10_1016_j_clineuro_2021_106893 crossref_primary_10_1177_03331024221137091 crossref_primary_10_1186_s10194_022_01438_4 crossref_primary_10_3390_ijms20143527 crossref_primary_10_3390_ph14020092 crossref_primary_10_1186_s12883_020_01775_4 crossref_primary_10_1016_j_clineuro_2020_105900 crossref_primary_10_1186_s10194_023_01594_1 crossref_primary_10_1007_s40120_023_00534_0 crossref_primary_10_1177_25158163221134593 |
| Cites_doi | 10.1212/WNL.55.6.754 10.1007/s11136-012-0230-7 10.1046/j.1468-1331.2002.00451.x 10.1016/S0140-6736(16)31678-6 10.1111/j.1468-2982.2005.01060.x 10.1177/0333102413485658 10.1046/j.1526-4610.1998.3804295.x 10.1001/jamaneurol.2017.3859 10.1046/j.1526-4610.2001.01156.x 10.1124/jpet.115.224212 10.1002/ana.410330109 10.1016/S1474-4422(14)70128-0 10.1212/WNL.0000000000004391 10.1212/01.wnl.0000252808.97649.21 10.1001/jamapsychiatry.2013.908 10.1212/WNL.0b013e3182535d20 10.1111/head.12891 10.1016/j.jpain.2014.11.004 10.1111/j.1526-4610.2006.00631.x 10.1046/j.1468-2982.1999.019002107.x 10.1007/s10194-009-0163-x 10.1016/S0140-6736(18)30478-1 10.1016/j.pain.2004.11.010 10.1111/head.12997 10.1007/s11886-014-0524-1 10.1212/WNL.56.suppl_1.S20 10.1111/j.1526-4610.2012.02117.x 10.1111/j.1468-1331.2009.02748.x 10.1111/head.13235 10.1002/ana.410280213 10.1176/appi.ajp.2011.10111704 10.1185/03007991003676461 10.1016/S0025-6196(11)60561-2 |
| ContentType | Journal Article |
| Copyright | The Author(s). 2018 COPYRIGHT 2018 BioMed Central Ltd. Copyright © 2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s). 2018 – notice: COPYRIGHT 2018 BioMed Central Ltd. – notice: Copyright © 2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TK 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12883-018-1193-2 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni Edition) ProQuest Central UK/Ireland ProQuest Central Essentials - QC ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2377 |
| EndPage | 12 |
| ExternalDocumentID | oai_doaj_org_article_4b01827d51e4461c8f6cb1686b9b5d41 PMC6234796 A567964200 30413151 10_1186_s12883_018_1193_2 |
| Genre | Randomized Controlled Trial Clinical Trial, Phase III Journal Article |
| GeographicLocations | United States United States--US |
| GeographicLocations_xml | – name: United States – name: United States--US |
| GrantInformation_xml | – fundername: Eli Lilly and Company funderid: http://dx.doi.org/10.13039/100004312 – fundername: ; |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABIVO ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EJD EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IGS IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB AAYXX AFFHD CITATION ALIPV CGR CUY CVF ECM EIF NPM 3V. 7TK 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c603t-c410cb446bbef14f2945594cbaa3334c2364d9361bd0c8fdaf2d0af13e2fbab23 |
| IEDL.DBID | BENPR |
| ISICitedReferencesCount | 98 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000449857300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1471-2377 |
| IngestDate | Fri Oct 03 12:33:48 EDT 2025 Tue Nov 04 01:55:49 EST 2025 Wed Oct 01 14:41:35 EDT 2025 Thu Oct 09 21:51:23 EDT 2025 Tue Nov 11 10:06:55 EST 2025 Tue Nov 04 18:05:05 EST 2025 Mon Jul 21 05:21:23 EDT 2025 Sat Nov 29 01:39:52 EST 2025 Tue Nov 18 21:48:02 EST 2025 Sat Sep 06 07:22:29 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Headache Galcanezumab CGRP Migraine |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c603t-c410cb446bbef14f2945594cbaa3334c2364d9361bd0c8fdaf2d0af13e2fbab23 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://www.proquest.com/docview/2135442130?pq-origsite=%requestingapplication% |
| PMID | 30413151 |
| PQID | 2135442130 |
| PQPubID | 44772 |
| PageCount | 12 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_4b01827d51e4461c8f6cb1686b9b5d41 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6234796 proquest_miscellaneous_2132224318 proquest_journals_2135442130 gale_infotracmisc_A567964200 gale_infotracacademiconefile_A567964200 pubmed_primary_30413151 crossref_primary_10_1186_s12883_018_1193_2 crossref_citationtrail_10_1186_s12883_018_1193_2 springer_journals_10_1186_s12883_018_1193_2 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-11-09 |
| PublicationDateYYYYMMDD | 2018-11-09 |
| PublicationDate_xml | – month: 11 year: 2018 text: 2018-11-09 day: 09 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BMC neurology |
| PublicationTitleAbbrev | BMC Neurol |
| PublicationTitleAlternate | BMC Neurol |
| PublicationYear | 2018 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | GBD 2015 Disease and Injury Incidence and Prevalence Collaborators (1193_CR1) 2016; 388 SD Silberstein (1193_CR16) 2012; 78 MA Ilgen (1193_CR9) 2013; 70 S Evers (1193_CR10) 2009; 16 LE Friedman (1193_CR37) 2018; 58 G Ifergane (1193_CR5) 2006; 26 WF Stewart (1193_CR28) 1999; 19 M Von Korff (1193_CR4) 2005; 113 RB Lipton (1193_CR2) 2007; 68 V Skljarevski (1193_CR24) 2017; 37 Suppl 1 HC Detke (1193_CR33) 2017; 37 Suppl 1 J VanderPluym (1193_CR18) 2016; 56 M Ashina (1193_CR38) 2017; 89 SD Silberstein (1193_CR14) 2017; 57 RB Lipton (1193_CR32) 2001; 41 P Jhingran (1193_CR27) 1998; 38 DW Dodick (1193_CR39) 2015; 16 DC Buse (1193_CR3) 2009; 84 Canadian Headache Society Guideline for Migraine Prophylaxis (1193_CR12) 2012; 39 Suppl 2 PJ Goadsby (1193_CR19) 1990; 28 PJ Goadsby (1193_CR20) 1993; 33 Headache Classification Committee of the International Headache Society (IHS) (1193_CR25) 2013; 33 1193_CR36 WF Stewart (1193_CR29) 2001; 56 1193_CR30 DW Dodick (1193_CR22) 2014; 13 N Breslau (1193_CR8) 2012; 52 Silberstein SD and the US Headache Consortium (1193_CR11) 2000; 55 R Rendas-Baum (1193_CR31) 2013; 22 R Malessa (1193_CR34) 2010; 26 S Sacco (1193_CR7) 2014; 16 S Vermeersch (1193_CR21) 2015; 354 G Nelles (1193_CR35) 2010; 11 K Hagen (1193_CR6) 2002; 9 TJ Steiner (1193_CR17) 2007; 8 K Posner (1193_CR26) 2011; 168 DW Dodick (1193_CR15) 2018; 391 S Diamond (1193_CR13) 2007; 47 V Skljarevski (1193_CR23) 2018; 75 |
| References_xml | – volume: 55 start-page: 754 year: 2000 ident: 1193_CR11 publication-title: Neurology doi: 10.1212/WNL.55.6.754 – volume: 22 start-page: 1123 year: 2013 ident: 1193_CR31 publication-title: Qual Life Res doi: 10.1007/s11136-012-0230-7 – volume: 9 start-page: 527 year: 2002 ident: 1193_CR6 publication-title: Eur J Neurol doi: 10.1046/j.1468-1331.2002.00451.x – volume: 388 start-page: 1545 year: 2016 ident: 1193_CR1 publication-title: Lancet doi: 10.1016/S0140-6736(16)31678-6 – volume: 37 Suppl 1 start-page: 339 year: 2017 ident: 1193_CR24 publication-title: Cephalalgia – volume: 26 start-page: 451 year: 2006 ident: 1193_CR5 publication-title: Cephalalgia doi: 10.1111/j.1468-2982.2005.01060.x – volume: 33 start-page: 629 year: 2013 ident: 1193_CR25 publication-title: Cephalalgia doi: 10.1177/0333102413485658 – volume: 38 start-page: 295 year: 1998 ident: 1193_CR27 publication-title: Headache doi: 10.1046/j.1526-4610.1998.3804295.x – ident: 1193_CR30 – volume: 75 start-page: 187 year: 2018 ident: 1193_CR23 publication-title: JAMA Neurol doi: 10.1001/jamaneurol.2017.3859 – volume: 41 start-page: 854 year: 2001 ident: 1193_CR32 publication-title: Headache doi: 10.1046/j.1526-4610.2001.01156.x – volume: 354 start-page: 350 year: 2015 ident: 1193_CR21 publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.115.224212 – volume: 33 start-page: 48 year: 1993 ident: 1193_CR20 publication-title: Ann Neurol doi: 10.1002/ana.410330109 – volume: 13 start-page: 885 year: 2014 ident: 1193_CR22 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(14)70128-0 – volume: 89 start-page: 1237 year: 2017 ident: 1193_CR38 publication-title: Neurology doi: 10.1212/WNL.0000000000004391 – volume: 68 start-page: 343 year: 2007 ident: 1193_CR2 publication-title: Neurology doi: 10.1212/01.wnl.0000252808.97649.21 – volume: 70 start-page: 692 year: 2013 ident: 1193_CR9 publication-title: JAMA Psychiatry doi: 10.1001/jamapsychiatry.2013.908 – volume: 78 start-page: 1337 year: 2012 ident: 1193_CR16 publication-title: Neurology doi: 10.1212/WNL.0b013e3182535d20 – volume: 56 start-page: 1335 year: 2016 ident: 1193_CR18 publication-title: Headache doi: 10.1111/head.12891 – volume: 16 start-page: 164 year: 2015 ident: 1193_CR39 publication-title: J Pain doi: 10.1016/j.jpain.2014.11.004 – volume: 47 start-page: 355 year: 2007 ident: 1193_CR13 publication-title: Headache doi: 10.1111/j.1526-4610.2006.00631.x – volume: 19 start-page: 107 year: 1999 ident: 1193_CR28 publication-title: Cephalalgia doi: 10.1046/j.1468-2982.1999.019002107.x – volume: 11 start-page: 33 year: 2010 ident: 1193_CR35 publication-title: J Headache Pain doi: 10.1007/s10194-009-0163-x – volume: 391 start-page: 1315 year: 2018 ident: 1193_CR15 publication-title: Lancet doi: 10.1016/S0140-6736(18)30478-1 – volume: 39 Suppl 2 start-page: S1 year: 2012 ident: 1193_CR12 publication-title: Can J Neurol Sci – volume: 113 start-page: 331 year: 2005 ident: 1193_CR4 publication-title: Pain doi: 10.1016/j.pain.2004.11.010 – volume: 37 Suppl 1 start-page: 338 year: 2017 ident: 1193_CR33 publication-title: Cephalalgia – volume: 57 start-page: 165 year: 2017 ident: 1193_CR14 publication-title: Headache doi: 10.1111/head.12997 – ident: 1193_CR36 – volume: 16 start-page: 524 year: 2014 ident: 1193_CR7 publication-title: Curr Cardiol Rep doi: 10.1007/s11886-014-0524-1 – volume: 56 start-page: S20 issue: Suppl 1 year: 2001 ident: 1193_CR29 publication-title: Neurology doi: 10.1212/WNL.56.suppl_1.S20 – volume: 8 start-page: S3 issue: Suppl 1 year: 2007 ident: 1193_CR17 publication-title: J Headache Pain. – volume: 52 start-page: 723 year: 2012 ident: 1193_CR8 publication-title: Headache doi: 10.1111/j.1526-4610.2012.02117.x – volume: 16 start-page: 968 year: 2009 ident: 1193_CR10 publication-title: Eur J Neurol doi: 10.1111/j.1468-1331.2009.02748.x – volume: 58 start-page: 371 year: 2018 ident: 1193_CR37 publication-title: Headache doi: 10.1111/head.13235 – volume: 28 start-page: 183 year: 1990 ident: 1193_CR19 publication-title: Ann Neurol doi: 10.1002/ana.410280213 – volume: 168 start-page: 1266 year: 2011 ident: 1193_CR26 publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.2011.10111704 – volume: 26 start-page: 1119 year: 2010 ident: 1193_CR34 publication-title: Curr Med Res Opin doi: 10.1185/03007991003676461 – volume: 84 start-page: 422 year: 2009 ident: 1193_CR3 publication-title: Mayo Clin Proc doi: 10.1016/S0025-6196(11)60561-2 |
| SSID | ssj0017841 |
| Score | 2.5221667 |
| Snippet | Background
Galcanezumab, a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide, has demonstrated in previous Phase 2... Galcanezumab, a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide, has demonstrated in previous Phase 2 and Phase 3... Background Galcanezumab, a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide, has demonstrated in previous Phase 2... Abstract Background Galcanezumab, a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide, has demonstrated in previous... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 188 |
| SubjectTerms | Adolescent Adult Aged Analysis Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Calcitonin Calcitonin gene-related peptide CGRP Chronic illnesses Clinical trials Double-Blind Method Drug dosages Electrocardiography Female Galcanezumab Headache Headaches Humans Injection Laboratories Male Medicine Medicine & Public Health Middle Aged Migraine Migraine Disorders - drug therapy Monoclonal antibodies Neurochemistry Neurology Neurosurgery Nonsteroidal anti-inflammatory drugs Pain Patients Peptides Pharmaceutical industry Prevention Psychopharmacology Quality of life Questionnaires Research Article Respiratory tract diseases Rhinopharyngitis Safety Sinusitis Studies Suicides & suicide attempts Treatment Outcome Vital signs Young Adult |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQhRAXxJvQgoyEhAS16lec-LggChcqDiB6s_xKu9I2WzW7SPTXM3a8S1MEXLjkEDuRPQ_7m4zzDUIvYf1zPlhGhGOKyCg40Zo3AOQarZjlnap9LjbRHB21x8f685VSX-lM2EgPPAruQDoKELgJNYsQuTDfdsrDa1vltKtD_mWdA-rZBFMlf5CyaSWHyVp1MLBUVBfCZoiYALEQPtmFMln_70vylT3p-nnJa0nTvBcd3kV3CojEs3Hw99CN2N9Htz6VNPkD9G2Gz09he8JiHy-W_QlJ6-8-TpWyCGg9LvBgu7j6gTO5LF52-INdgIzj5frMOjzvcaFbHXD6TovP5iepkkR8iL4evv_y7iMpFRSIV1SsiJeMegdycy52THZcS4ggpHfWCiGkT-zxQQvFXKAg2WA7HqjtmIi8c9Zx8Qjt9Ms-PkHYU-Yg9NEBQi4JMRIAC0ZdDFo5aUWIFaIbiRpf6MVTlYuFyWFGq8yoBANKMEkJhlfo9faR85Fb42-d3yY1bTsmWux8A4zFFGMx_zKWCr1KSjbJeWFw3pZ_EGCKiQbLzOr0WU3CylGhvUlPcDo_bd6YiSlOPxjORC0lXKH5xbY5PZkOsvVxuc59AJEBamsr9Hi0qu2UBAVEAQisQs3E3iZznrb089NMCQ4gVsLQKvRmY5m_hvVHkT79HyLdRbf56FeE6j20s7pYx2fopv--mg8Xz7NX_gTbmzZR priority: 102 providerName: Directory of Open Access Journals – databaseName: SpringerLink Contemporary (1997 - Present) dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9QwELZQQYgX7iOlICMhIUEj4iNO_LggCi9UiLNvlq9sV9om1Wa3Evx6xl4nkHJI8JKHeCx57G-ujDOD0GPQf8Y6TXJmiMi5ZzSXklbgyFVSEE0bUdrYbKI6PKyPjuS79B93P9x2H1KSUVNHsa7F856ExrgQ-kLUA15HDnr3Ili7Okjj-w-fx9RBSKSl9OVvp00MUKzT_6s2_skcnb8qeS5fGs3QwbX_YuA6upq8TjzbwuQGuuDbm-jy25RXv4W-zPDpMdgzzPbxsmvneVDY-zi01soBJn6Je9349Vccq9HirsGv9RIOxX_bnGiDFy1O9Vl7HD7s4pPFPLSe8LfRp4NXH1--yVPLhdyKgq1zy0lhDYSIxviG8IZKDiEHt0Zrxhi3ody8k0wQ4wpbN0431BW6IczTxmhD2R2003atv4ewLYiBWEk6iNE4BFXgiZDCeCeF4Zo5n6FiOAdlUz3y0BZjqWJcUgu13TAFG6bChimaoafjlNNtMY6_Eb8IhzsShjra8UW3mqskloobmEArVxIPTBNgSVgAbS2MNKXjJENPAjRUkHZYnNXppwVgMdTNUrMyfIfjoGoytDehBCm10-EBXCppiV5RwkrO4QnDj8bhMDPcfGt9t4k04MKBm1dn6O4WiyNLrAAXBFy2DFUTlE54no60i-NYQxy8Xg5Ly9CzAas_lvXHLd39J-r76Ardgj0v5B7aWa82_gG6ZM_Wi371MArtd5t8Ops priority: 102 providerName: Springer Nature |
| Title | A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine |
| URI | https://link.springer.com/article/10.1186/s12883-018-1193-2 https://www.ncbi.nlm.nih.gov/pubmed/30413151 https://www.proquest.com/docview/2135442130 https://www.proquest.com/docview/2132224318 https://pubmed.ncbi.nlm.nih.gov/PMC6234796 https://doaj.org/article/4b01827d51e4461c8f6cb1686b9b5d41 |
| Volume | 18 |
| WOSCitedRecordID | wos000449857300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMed Central Open Access Free customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: RBZ dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: DOA dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: M~E dateStart: 20010101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLink Contemporary customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: RSV dateStart: 20011201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bb9MwFD5iHUK8cL8ERmUkJCRYtPjSXJ5QhzbgYVU1buXJsh2nq9QlpWmR4NdznLoZGWIvvERybEs-OcfH5-J8B-AF6j9tckVDrmkcCstZmGUsQUMuyWKqWBEPTFNsIhmN0skkG_uAW-2vVW51YqOo88q4GPkBo3wgBD6jN4vvoasa5bKrvoTGDuw6pDLRg93Do9H4tM0juKyaz2XSND6oqSuui-4zek5ouYSscxo1oP1_q-Y_zqbL9yYvJU-bM-n49v9ScwdueWuUDDficxeu2fIe3Djx-fb78HVIFmd4zhG-T-ZVOQ2dIt8nruRWiOJj56RWhV39JA1KLakK8k7NkVn21_pcaTIricdtrYkL-JLz2dSVpLAP4PPx0ae370NfiiE0ccRXoRE0MhpdR61tQUXBMoGuiDBaKc65MA6GPs94THUembTIVcHySBWUW1ZopRl_CL2yKu1jICaiGn2oLEffTaCzhRYKjbTNs1gLxXMbQLRliTQep9yVy5jLxl9JY7nhokQuSsdFyQJ41U5ZbEA6rhp86PjcDnT42s2LajmVfrtKoXECS_IBtUg0RZJig8KcxjrTg1zQAF46KZFOC-DijPI_MyCJDk9LDgcuPidQBQWw1xmJu9d0u7cCIr32qOWFdATwvO12M92NuNJW62YMmnZo_qUBPNqIZUsSj9A0QVMugKQjsB2auz3l7KzBFkdrWODSAni9Fe2LZf3zkz65moincHNz58IFrvagt1qu7TO4bn6sZvWyDzvJJGmead9v334TGcHW-MPJ-Bu2Tj9--Q07yUuv |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB5VLQIuvB-BAkYCIUGjxo9kkwNCy6N01e5qD0WUk7EdZ7vSNln2ASo_it_IOI8tKaK3HrjsYW1LnuSbb2Y8zgzAM-Q_bVJFfa5p5AvLmZ8krIOOXCeJqGJZFJqy2URnMIgPD5PhGvxqvoVx1yobTiyJOi2MOyPfZpSHQuBv8Gb6zXddo1x2tWmhUcFiz578wJBt_rr3Ht_vc8Z2Phy82_XrrgK-iQK-8I2ggdEYBWltMyoylgj0qoXRSnHOhXEV1dOER1SngYmzVGUsDVRGuWWZVtoVOkDK38C9hPE6bAx7_eGXVd7CZfHq3CmNo-05dc18MVzHSA09JZ-1rF_ZJOBvU_CHLTx7T_NMsra0gTvX_7endwOu1d426VbqcRPWbH4LLvfr-wS34XOXTI_QjhO-RSZFPvKdodoirqWYj-phJ2SuMrs4IWUVXlJk5KOaIBjtz-Wx0mSck7ou7Zy4A21yPB65lhv2Dny6ELHuwnpe5PY-EBNQjTFikmJsKjCYRA-MBtqmSaSF4qn1IGggIE1dh921A5nIMh6LI1mhRiJqpEONZB68XC2ZVkVIzpv81uFqNdHVDy__KGYjWdORFBoXsE4aUotCUxQpMqiscaQTHaaCevDCoVI6lsPNGVV_rIEiunphshu680eBFOvBZmsmspNpDzeAlDU7zuUpGj14uhp2K92Nv9wWy3IOuq7o3sYe3KvUYCUSD9D1QlfVg05LQVoyt0fy8VFZOx29fYFb8-BVo0qn2_rnI31wvhBP4MruQX9f7vcGew_hKqvU3Q-STVhfzJb2EVwy3xfj-exxTRcEvl60jv0GxrmlUg |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1ZixQxEA6yyuKLt2vrqhEEQbfZztHX43iMijoseO1byDk7MNs9TPcI-uutdKdHez1AfOmHTgVSlUqlKpV8hdBDsH9KG0lipkgWc8toXJY0B0cuLzMiqctS3RWbyGez4vi4PAp1TpvhtvuQkuzfNHiUpqo9XBnXL_EiO2yIL5ILYTBEQOCBxGCDz3NfM8iH6-8_bdMIPqkWUpm_7TbajDrM_l8t809b09lrk2dyp92WNL3838xcQZeCN4onvfpcRedsdQ3tvgv59uvo8wSvTmCfw-wAL-tqHntDfoB9ya0Y1McucSOdbb_iDqUW1w6_lEuYLPttcyoVXlQ44LY22B_44tPF3JeksDfQx-mLD89exaEUQ6yzhLWxBulqBaGjUtYR7mjJIRThWknJGOPaw9CbkmVEmUQXzkhHTSIdYZY6JRVlN9FOVVf2FsI6IQpiqNJA7MYh2AIPhSTKmjJTXDJjI5QMcyJ0wCn35TKWootXikz0AhMgMOEFJmiEHm-7rHqQjr8RP_UTvSX0-Nrdj3o9F2G5Cq6gA81NSiwwTYClTIMyF5kqVWo4idAjrybCWwEYnJbhMQOw6PG0xCT153McTFCE9keUsHr1uHlQNBGsRyMoYSnn8IXmB9tm39PfiKtsvelowLUD96-I0F6vl1uWWAKuCbhyEcpHGjviedxSLU46bHHwhjkMLUJPBr39Maw_ivT2P1HfR7tHz6fi7evZmzvoIu31Pk7KfbTTrjf2Lrqgv7SLZn2vW8vfAX_qRmM |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+phase+3%2C+long-term%2C+open-label+safety+study+of+Galcanezumab+in+patients+with+migraine&rft.jtitle=BMC+neurology&rft.au=Camporeale%2C+Angelo&rft.au=Kudrow%2C+David&rft.au=Sides%2C+Ryan&rft.au=Wang%2C+Shufang&rft.date=2018-11-09&rft.pub=BioMed+Central&rft.eissn=1471-2377&rft.volume=18&rft_id=info:doi/10.1186%2Fs12883-018-1193-2&rft_id=info%3Apmid%2F30413151&rft.externalDocID=PMC6234796 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2377&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2377&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2377&client=summon |